Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme Therapeutics (NASDAQ: HALO) has expanded its collaboration with argenx, adding exclusive access to its ENHANZE® drug delivery technology for three new targets. This brings the total to six targets under the agreement initiated in February 2019. argenx is advancing the development of its FcRn antagonist efgartigimod and has also nominated a complement inhibitor targeting C2. The collaboration aims to improve patient experiences by enabling subcutaneous delivery options for various therapies. Halozyme derives revenues through milestones and royalties from these partnerships.
Halozyme Therapeutics (NASDAQ: HALO) announced that Roche presented data from the Phase 1b study evaluating atezolizumab (Tecentriq) for subcutaneous use through Halozyme's ENHANZE technology at the ESMO Virtual Congress 2020. The study, involving 67 patients with advanced non-small cell lung cancer, showed that the subcutaneous formulation was well-tolerated and had similar exposure to the intravenous version. This supports further development in the Phase 3 study, potentially improving treatment efficiency by reducing administration time.
Halozyme Therapeutics announced that Janssen Biotech submitted a supplemental Biologics License Application (sBLA) to the FDA for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to treat light chain (AL) amyloidosis, a serious disease with no approved therapies. The application is backed by positive results from the Phase 3 ANDROMEDA study, which achieved its primary endpoint. This sBLA is evaluated under the FDA's Real-Time Oncology Review program, aiming for expedited patient access to treatments. The approval process does not guarantee success.
Halozyme Therapeutics (NASDAQ: HALO) announced that Dr. Helen Torley, President and CEO, will participate in two upcoming investor conferences. The first is the Cantor Virtual Global Healthcare Conference scheduled for September 15, 2020, at 10:40 a.m. ET, and the second is the Morgan Stanley Virtual Global Healthcare Conference on September 17, 2020, at 2:00 p.m. ET. Live webcasts of both events will be available on Halozyme's website, along with an archive for 90 days post-event. Halozyme specializes in biopharmaceutical solutions, notably through its ENHANZE® technology.
Halozyme Therapeutics (NASDAQ: HALO) CEO Dr. Helen Torley will speak at the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 10:00 a.m. ET. Interested participants can access a live webcast through the "Investors" section of Halozyme's website, with an archive available for 90 days post-event. Halozyme specializes in biopharmaceutical solutions, particularly through its ENHANZE® technology that streamlines drug delivery, benefiting over 400,000 patients globally. The company partners with leading firms to enhance treatment efficiency and patient experiences.
Halozyme Therapeutics reported strong Q2 2020 results, achieving its first profitable quarter with earnings per share of $0.19. The company secured multiple FDA and EMA approvals for drugs utilizing its ENHANZE® technology, including Janssen's subcutaneous DARZALEX® and Roche's Phesgo™. Q2 revenue rose to $55.2 million, up from $39.1 million year-over-year, primarily driven by collaboration payments. Halozyme maintains its 2020 revenue guidance of $230 million to $245 million despite potential COVID-19 impacts, emphasizing its commitment to sustainable profitability and capital return through share repurchases.
Halozyme Therapeutics (NASDAQ: HALO) announced Dr. Helen Torley, CEO, will participate in the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 8:30 a.m. ET. A live webcast will be available on Halozyme's website, with an archive accessible for 90 days post-event. Halozyme focuses on optimizing patient experiences and outcomes through its ENHANZE® technology, which facilitates faster drug delivery, benefiting over 400,000 patients globally. The company collaborates with industry leaders to advance innovative therapies.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host a Quarterly Update Conference Call on August 10, 2020, at 4:30 p.m. ET to discuss its second quarter 2020 financial results, which will be released after market close. Dr. Helen Torley, the CEO, will lead the call. Interested participants can register via a link provided in the announcement. The event will be available for live streaming through the Investors section of Halozyme's website, with a recording accessible afterward. A telephone replay will be available for two weeks post-call.
Summary not available.
Halozyme Therapeutics (NASDAQ: HALO) has announced that Dr. Helen Torley, the president and CEO, will participate in the BMO 2020 Prescriptions for Success Healthcare Conference. The virtual event will be held on June 23, 2020, at 3:00 p.m. ET / 12:00 p.m. PT. A live webcast will be available through the Investors section of Halozyme's website, with an archive accessible for 90 days after the event. Halozyme specializes in innovative solutions for drug delivery, significantly enhancing patient experiences and outcomes through their proprietary ENHANZE® technology.
FAQ
What is the current stock price of Halozyme Thrp (HALO)?
What is the market cap of Halozyme Thrp (HALO)?
